At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 65 enrolled
Drug / intervention
CP-751,871drug
Likely dose
CP-751,871 20 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating CP-751,871 for Sarcoma, Ewing's. Completed, enrolled 65 participants across 3 sites in 2 countries.
Detailed Summary
This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma, Ewing's
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2005
First PostedMay 2007
Primary CompletionJan 2011
Study CompletionOct 2012
TodayJul 2026
First PostedMay 17, 2007
Enrollment StartAug 1, 2005
Primary CompletionJan 1, 2011
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 19.1 years ago
Interventions
CP-751,871drug
Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity